BCMA Targeted Therapies in Patients With TTP Relapse

Immune-Mediated Thrombotic Thrombocytopenic Perpura is a rare, life-threatening autoimmune condition characterized by an acquired deficiency of the von Willibrand Factor Cleaving Protein, ADAM-TS13. If not treated promptly, TTP is associated with significant morbidity and mortality. Over the last decade, the chimeric anti-CD-20 monoclonal antibody Rituximab has become a treatment of choice in TTP. Approximately 15% to 30% of patients with TTP relapse by the two-year mark; rates increase with duration of follow-up.